Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15946
Abstract: Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors.… read more here.
Keywords: bullous pemphigoid; omalizumab corticosteroid; bp180 bp230; pemphigoid ... See more keywords
Bullous pemphigoid: more than one disease?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15445
Abstract: Bullous pemphigoid (BP) is an organ-specific autoimmune disease of the skin, characterized and caused by autoantibodies targeting BP180 and/or BP230. In the ‘classical’ and name-giving variant, BP patients present with blisters on inflamed skin. Yet,… read more here.
Keywords: autoantibody; bp230; bp180 bp230; disease ... See more keywords
Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid
Sign Up to like & getrecommendations! Published in 2023 at "Indian Journal of Dermatology"
DOI: 10.4103/ijd.ijd_248_22
Abstract: Bullous pemphigoid (BP) is a chronic subepidermal immunobullous disorder. Studies have demonstrated the presence of antibasement membrane zone antibodies (BP180 & BP230) in the blister fluid using enzyme-linked immunosorbent assay (ELISA). To detect and compare… read more here.
Keywords: bullous pemphigoid; blister fluid; serum; fluid serum ... See more keywords